GIST Patients Treated with Imatinib

This retrospective study was conducted at the First Affiliated Hospital of Chongqing Medical University. From April 2015 to December 2018, only patients with a primary GIST diagnosis who underwent surgery with curative intent (R0) were included in this study. The inclusion criteria were as follows: (1) pathologically confirmed GIST; (2) according to the guidelines and expert consensus (7 (link), 8 (link)), patients were identified with an intermediate or high risk of relapse, with at least one of the following features: longest tumor diameter of >10.0 cm and mitotic count >10 mitoses per 50 high-power fields of the microscope, a tumor diameter of >5.0 cm and mitotic count >5 mitoses per 50 high-power fields of the microscope, a small intestinal tumor diameter >5.0 cm or mitotic count >5 mitoses per 50 high-power fields of the microscope, or tumor rupture before surgery or at surgery; (3) IM taken by patients was produced by Novartis (Switzerland); (4) patients with GIST took IM at a fixed 400 mg daily dose; and (5) good compliance (take IM regularly). The exclusion criteria were as follows: (1) serious comorbidity; (2) oral administration restricted because of significant gastrointestinal bleeding or obstruction; (3) treatment with drugs known to induce or inhibit CYP3A4 or P-glycoprotein and inhibit the human organic cation transporter 1 if no alternative medication was available, or if the patient was unwilling to change the medication.